Current Report Filing (8-k)
May 18 2016 - 4:17PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May 11, 2016
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
333-190456
|
|
22-2983783
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
201
Grove Road
Thorofare,
NJ 080086
(Address
of Principal Executive Offices)
(856)
848-2116
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
May 11, 2016, the Board of Directors (the “Board”) of the Akers Biosciences, Inc. (the “Company”) amended
our Amended and Restated By-Laws (the “By-Laws”) to reduce the quorum for a meeting of the stockholders, from holders
of 40% in voting power of the outstanding shares of stock to the holders of 33.34% in voting power of the outstanding shares of
stock (the “Amendment”). The reason for the Amendment is primarily to be able to obtain a quorum and conduct business
at shareholder meetings.
The
foregoing descriptions of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the
Amendment, a copy of which is attached hereto as Exhibit 3.6, and incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
|
|
Description
|
|
|
|
3.6*
|
|
Amendment
to Amended and Restated By-Laws, dated May 11, 2016.
|
*
Filed herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
|
Date:
May 18, 2016
|
By:
|
/s/
John Gormally
|
|
|
John
Gormally
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024